Bibliography

1. **Sumit Kinger,** Jagtap, Y.A., Dubey, A.R., Kumar, P., Choudhary, A., Dhiman, R., Prajapati, V.K., Chitkara, D., Poluri, K.M. and **Amit Mishra,** 2024. Lanosterol elevates cytoprotective response through induced-proteasomal degradation of aberrant proteins. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*, 1871(2), p.119631.
2. **Sumit Kinger,** Jagtap, Y.A., Dubey, A.R., Kumar, P., Choudhary, A., Karmakar, S., Lal, G., Prajapati, V. K., Jha, H. C., Gutti, R. K. and **Amit Mishra,** 2024. Valproate Mediated Proteasome Dysfunctions Induces Apoptosis *Advanced Therapeutics*, p.2300421.
3. **Sumit Kinger,** Jagtap, Y.A., Kumar, P., Choudhary, A., Prasad, A., Prajapati, V. K., Kumar, A., Mehta, G., and **Amit Mishra,** 2024. Proteostasis in Neurodegenerative Diseases *Advances in Clinical Chemistry*, 121, pp. 270-333
4. **Sumit Kinger,** Dubey, A.R., Kumar, P., Jagtap, Y.A., Choudhary, A., Kumar, A., Prajapati, V.K., Dhiman, R. and **Amit Mishra,** 2023. Molecular Chaperones' Potential against Defective Proteostasis of Amyotrophic Lateral Sclerosis. *Cells*, 12(9), p.1302.
5. Kumar, P., **Sumit Kinger,** Dubey, A.R., Jagtap, Y.A., Choudhary, A., Prasad, A., Jha, H.C., Dhiman, R., Gutti, R.K. and **Amit Mishra,** 2023. Trehalose Promotes Clearance of Proteotoxic Aggregation of Neurodegenerative Disease-Associated Aberrant Proteins. *Molecular Neurobiology*, pp.1-19.
6. Jagtap, Y.A., Kumar, P., Dubey, A.R., **Sumit Kinger,** Choudhary, A., Karmakar, S., Lal, G., Kumar, A., Kumar, A., Prasad, A. and **Amit Mishra**, 2024. Acetaminophen induces mitochondrial apoptosis through proteasome dysfunctions. *Life Sciences*, p.122732.
7. Kumar, P., Choudhary, A., **Sumit Kinger,** Jagtap, Y.A., Dubey, A.R., Gutti, R.K., Chitkara, D., Suresh, A.K. and **Amit Mishra,** 2023. Proteostasis defects: Medicinal challenges of imperfect aging & neurodegeneration. *Translational Medicine of Aging*.
8. Dubey, A.R., Mishra, R., Jagtap, Y.A., **Sumit Kinger,** Kumar, P., Dhiman, R., Ghosh, S., Singh, S., Prasad, A., Jana, N.R. and **Amit Mishra,** 2023. Itraconazole Confers Cytoprotection Against Neurodegenerative Disease-Associated Abnormal Protein Aggregation. *Molecular Neurobiology*, 60(5), pp.2397-2412.
9. Jagtap, Y.A., Kumar, P., **Sumit Kinger,** Dubey, A.R., Choudhary, A., Gutti, R.K., Singh, S., Jha, H.C., Poluri, K.M. and **Amit Mishra,** 2023. Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing. *Frontiers in Cell and Developmental Biology*, 11, p.1146564.
10. Dubey, A.R., Mishra, R., Sundaria, N., Jagtap, Y.A., Kumar, P., **Sumit Kinger,** Choudhary, A., Jha, H.C., Prasad, A., Gutti, R.K. and **Amit Mishra,** 2022. Resveratrol promotes LRSAM1 E3 ubiquitin ligase-dependent degradation of misfolded proteins linked with neurodegeneration. *Cell Physiol Biochem*, 56(5), pp.530-545.
11. Dubey, A.R., Patwa, S.M., **Sumit Kinger,** Jagtap, Y.A., Kumar, P., Singh, S., Dhiman, R., Jha, H.C. and **Amit Mishra,** 2022. Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases? *Molecular Neurobiology*, 59(6), pp.3382-3401.
12. Kumar, P., Jagtap, Y.A., Patwa, S.M., **Sumit Kinger,** Dubey, A.R., Prajapati, V.K., Dhiman, R., Poluri, K.M. and **Amit Mishra,** 2022. Autophagy based cellular physiological strategies target oncogenic progression. *Journal of Cellular Physiology*, 237(1), pp.258-277.
13. Dubey, A.R., **Sumit Kinger,** Jagtap, Y.A., Patwa, S.M., Kumar, P., Singh, S., Kumar, A., Kumar, A. and **Amit Mishra,** 2021. Proteasome Based Molecular Strategies Against Improper Cellular

Proliferation. *Cellular Physiology & Biochemistry* (Cell Physiol Biochem Press GmbH & Co. KG), 55.

14. Dubey, A.R., Jagtap, Y.A., Kumar, P., Patwa, S.M., **Sumit Kinger,** Kumar, A., Singh, S., Prasad, A., Jana, N.R. and **Amit Mishra,** 2022. Biochemical strategies of E3 ubiquitin ligases target viruses in critical diseases. *Journal of Cellular Biochemistry*, 123(2), pp.161-182.

References

Abramov, A.Y., Potapova, E.V., Dremin, V.V., and Dunaev, A.V. (2020). Interaction of Oxidative Stress and Misfolded Proteins in the Mechanism of Neurodegeneration. *Life (Basel)* 10.

Adams, J. (2003). The proteasome: structure, function, and role in the cell. *Cancer Treat Rev* 29 Suppl 1**,** 3-9.

Adams, J. (2004). The development of proteasome inhibitors as anticancer drugs. *Cancer Cell* 5**,** 417-421.

Agarraberes, F.A., and Dice, J.F. (2001). A molecular chaperone complex at the lysosomal membrane is required for protein translocation. *J Cell Sci* 114**,** 2491-2499.

Almond, J.B., and Cohen, G.M. (2002). The proteasome: a novel target for cancer chemotherapy. *Leukemia* 16**,** 433-443.

Alvarez-Erviti, L., Rodriguez-Oroz, M.C., Cooper, J.M., Caballero, C., Ferrer, I., Obeso, J.A., and Schapira, A.H. (2010). Chaperone-mediated autophagy markers in Parkinson disease brains. *Arch Neurol* 67**,** 1464-1472.

Amanullah, A., Upadhyay, A., Chhangani, D., Joshi, V., Mishra, R., Yamanaka, K., and Mishra, A. (2017a). Proteasomal Dysfunction Induced By Diclofenac Engenders Apoptosis Through Mitochondrial Pathway. *J Cell Biochem* 118**,** 1014-1027.

Amanullah, A., Upadhyay, A., Joshi, V., Mishra, R., Jana, N.R., and Mishra, A. (2017b). Progressing neurobiological strategies against proteostasis failure: Challenges in neurodegeneration. *Prog Neurobiol* 159**,** 1-38.

Amm, I., Sommer, T., and Wolf, D.H. (2014). Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. *Biochim Biophys Acta* 1843**,** 182-196.

Andreasson, C., Fiaux, J., Rampelt, H., Druffel-Augustin, S., and Bukau, B. (2008). Insights into the structural dynamics of the Hsp110-Hsp70 interaction reveal the mechanism for nucleotide exchange activity. *Proc Natl Acad Sci U S A* 105**,** 16519-16524.

Arlt, A., Bauer, I., Schafmayer, C., Tepel, J., Muerkoster, S.S., Brosch, M., Roder, C., Kalthoff, H., Hampe, J., Moyer, M.P., Folsch, U.R., and Schafer, H. (2009). Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). *Oncogene* 28**,** 3983-3996.

Arslan, M.A., Chikina, M., Csermely, P., and Soti, C. (2012). Misfolded proteins inhibit proliferation and promote stress-induced death in SV40-transformed mammalian cells. *FASEB J* 26**,** 766-777.

Balch, W.E., Morimoto, R.I., Dillin, A., and Kelly, J.W. (2008). Adapting proteostasis for disease intervention. *Science* 319**,** 916-919.

Balchin, D., Hayer-Hartl, M., and Hartl, F.U. (2016). In vivo aspects of protein folding and quality control. *Science* 353**,** aac4354.

Barrera, M.J., Aguilera, S., Castro, I., Gonzalez, S., Carvajal, P., Molina, C., Hermoso, M.A., and Gonzalez, M.J. (2018). Endoplasmic reticulum stress in autoimmune diseases: Can altered protein quality control and/or unfolded protein response contribute to autoimmunity? A critical review on Sjogren's syndrome. *Autoimmun Rev* 17**,** 796-808.

Basanta, D., and Anderson, A.R.A. (2017). Homeostasis Back and Forth: An Ecoevolutionary Perspective of Cancer. *Cold Spring Harb Perspect Med* 7.

Bates, G.P., Dorsey, R., Gusella, J.F., Hayden, M.R., Kay, C., Leavitt, B.R., Nance, M., Ross, C.A., Scahill, R.I., Wetzel, R., Wild, E.J., and Tabrizi, S.J. (2015). Huntington disease. *Nat Rev Dis Primers* 1**,** 15005.

Bedford, L., Lowe, J., Dick, L.R., Mayer, R.J., and Brownell, J.E. (2011). Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. *Nat Rev Drug Discov* 10**,** 29-46.

Bence, N.F., Sampat, R.M., and Kopito, R.R. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. *Science* 292**,** 1552-1555.
Bengtson, M.H., and Joazeiro, C.A. (2010). Role of a ribosome-associated E3 ubiquitin ligase in protein quality control. *Nature* 467**,** 470-473.
Bento, C.F., Renna, M., Ghislat, G., Puri, C., Ashkenazi, A., Vicinanza, M., Menzies, F.M., and Rubinsztein, D.C. (2016). Mammalian Autophagy: How Does It Work? *Annu Rev Biochem* 85**,** 685-713.
Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., Palladini, G., Giuliani, N., Anderson, K.C., Sitia, R., and Cenci, S. (2009). The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. *Blood* 113**,** 3040-3049.
Biebl, M.M., and Buchner, J. (2019). Structure, Function, and Regulation of the Hsp90 Machinery. *Cold Spring Harb Perspect Biol* 11.
Bo Kim, K. (2021). Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance? *Cancer Drug Resist* 4**,** 634-645.
Brandman, O., and Hegde, R.S. (2016). Ribosome-associated protein quality control. *Nat Struct Mol Biol* 23**,** 7-15.
Brehme, M., Voisine, C., Rolland, T., Wachi, S., Soper, J.H., Zhu, Y., Orton, K., Villella, A., Garza, D., Vidal, M., Ge, H., and Morimoto, R.I. (2014). A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. *Cell Rep* 9**,** 1135-1150.
Bruijn, L.I., Houseweart, M.K., Kato, S., Anderson, K.L., Anderson, S.D., Ohama, E., Reaume, A.G., Scott, R.W., and Cleveland, D.W. (1998). Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. *Science* 281**,** 1851-1854.
Buetow, L., and Huang, D.T. (2016). Structural insights into the catalysis and regulation of E3 ubiquitin ligases. *Nat Rev Mol Cell Biol* 17**,** 626-642.
Bush, K.T., Goldberg, A.L., and Nigam, S.K. (1997). Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. *J Biol Chem* 272**,** 9086-9092.
Calderwood, S.K., and Gong, J. (2016). Heat Shock Proteins Promote Cancer: It's a Protection Racket. *Trends Biochem Sci* 41**,** 311-323.
Carra, S., Seguin, S.J., Lambert, H., and Landry, J. (2008). HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. *J Biol Chem* 283**,** 1437-1444.
Chai, Y., Koppenhafer, S.L., Shoesmith, S.J., Perez, M.K., and Paulson, H.L. (1999). Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. *Hum Mol Genet* 8**,** 673-682.
Cheetham, M.E., and Caplan, A.J. (1998). Structure, function and evolution of DnaJ: conservation and adaptation of chaperone function. *Cell Stress Chaperones* 3**,** 28-36.
Chen, B., Retzlaff, M., Roos, T., and Frydman, J. (2011). Cellular strategies of protein quality control. *Cold Spring Harb Perspect Biol* 3**,** a004374.
Chen, L., Brewer, M.D., Guo, L., Wang, R., Jiang, P., and Yang, X. (2017). Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis. *Cell Rep* 18**,** 3143-3154.
Chen, S., Ye, J., Chen, X., Shi, J., Wu, W., Lin, W., Lin, W., Li, Y., Fu, H., and Li, S. (2018). Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-kappaB pathway dependent of HDAC3. *J Neuroinflammation* 15**,** 150.
Chen, X., Wong, P., Radany, E., and Wong, J.Y. (2009). HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. *Cancer Biother Radiopharm* 24**,** 689-699.
Chhangani, D., and Mishra, A. (2013). Protein quality control system in neurodegeneration: a healing company hard to beat but failure is fatal. *Mol Neurobiol* 48**,** 141-156.
Chiang, H.L., Terlecky, S.R., Plant, C.P., and Dice, J.F. (1989). A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. *Science* 246**,** 382-385.

Chiosis, G., Digwal, C.S., Trepel, J.B., and Neckers, L. (2023). Structural and functional complexity of HSP90 in cellular homeostasis and disease. *Nat Rev Mol Cell Biol* 24**,** 797-815.

Chondrogianni, N., Voutetakis, K., Kapetanou, M., Delitsikou, V., Papaevgeniou, N., Sakellari, M., Lefaki, M., Filippopoulou, K., and Gonos, E.S. (2015). Proteasome activation: An innovative promising approach for delaying aging and retarding age-related diseases. *Ageing Res Rev* 23**,** 37-55.

Chu, J., Hong, N.A., Masuda, C.A., Jenkins, B.V., Nelms, K.A., Goodnow, C.C., Glynne, R.J., Wu, H., Masliah, E., Joazeiro, C.A., and Kay, S.A. (2009). A mouse forward genetics screen identifies LISTERIN as an E3 ubiquitin ligase involved in neurodegeneration. *Proc Natl Acad Sci U S A* 106**,** 2097-2103.

Chun, Y., and Kim, J. (2018). Autophagy: An Essential Degradation Program for Cellular Homeostasis and Life. *Cells* 7.

Ciechanover, A., and Kwon, Y.T. (2015). Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. *Exp Mol Med* 47**,** e147.

Ciechanover, A., and Kwon, Y.T. (2017). Protein Quality Control by Molecular Chaperones in Neurodegeneration. *Front Neurosci* 11**,** 185.

Clague, M.J., Heride, C., and Urbe, S. (2015). The demographics of the ubiquitin system. *Trends Cell Biol* 25**,** 417-426.

Coleman, R.A., and Trader, D.J. (2018). All About the Core: A Therapeutic Strategy to Prevent Protein Accumulation with Proteasome Core Particle Stimulators. *ACS Pharmacol Transl Sci* 1**,** 140-142.

Connell, P., Ballinger, C.A., Jiang, J., Wu, Y., Thompson, L.J., Hohfeld, J., and Patterson, C. (2001). The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. *Nat Cell Biol* 3**,** 93-96.

Coronel, J., Cetina, L., Pacheco, I., Trejo-Becerril, C., Gonzalez-Fierro, A., De La Cruz-Hernandez, E., Perez-Cardenas, E., Taja-Chayeb, L., Arias-Bofill, D., Candelaria, M., Vidal, S., and Duenas-Gonzalez, A. (2011). A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. *Med Oncol* 28 Suppl 1**,** S540-546.

Crawford, L.J., Walker, B., and Irvine, A.E. (2011). Proteasome inhibitors in cancer therapy. *J Cell Commun Signal* 5**,** 101-110.

Crippa, V., D'agostino, V.G., Cristofani, R., Rusmini, P., Cicardi, M.E., Messi, E., Loffredo, R., Pancher, M., Piccolella, M., Galbiati, M., Meroni, M., Cereda, C., Carra, S., Provenzani, A., and Poletti, A. (2016). Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. *Sci Rep* 6**,** 22827.

Crippa, V., Sau, D., Rusmini, P., Boncoraglio, A., Onesto, E., Bolzoni, E., Galbiati, M., Fontana, E., Marino, M., Carra, S., Bendotti, C., De Biasi, S., and Poletti, A. (2010). The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). *Hum Mol Genet* 19**,** 3440-3456.

Cristofani, R., Crippa, V., Vezzoli, G., Rusmini, P., Galbiati, M., Cicardi, M.E., Meroni, M., Ferrari, V., Tedesco, B., Piccolella, M., Messi, E., Carra, S., and Poletti, A. (2018). The small heat shock protein B8 (HSPB8) efficiently removes aggregating species of dipeptides produced in C9ORF72-related neurodegenerative diseases. *Cell Stress Chaperones* 23**,** 1-12.

Cuellar, J., Martin-Benito, J., Scheres, S.H., Sousa, R., Moro, F., Lopez-Vinas, E., Gomez-Puertas, P., Muga, A., Carrascosa, J.L., and Valpuesta, J.M. (2008). The structure of CCT-Hsc70 NBD suggests a mechanism for Hsp70 delivery of substrates to the chaperonin. *Nat Struct Mol Biol* 15**,** 858-864.

Cuervo, A.M. (2004). Autophagy: in sickness and in health. *Trends Cell Biol* 14**,** 70-77.

Cuervo, A.M. (2011). Chaperone-mediated autophagy: Dice's 'wild' idea about lysosomal selectivity. *Nat Rev Mol Cell Biol* 12**,** 535-541.

Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., and Sulzer, D. (2004). Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. *Science* 305**,** 1292-1295.

De Duve, C., and Wattiaux, R. (1966). Functions of lysosomes. *Annu Rev Physiol* 28**,** 435-492.

De Maio, A., Santoro, M.G., Tanguay, R.M., and Hightower, L.E. (2012). Ferruccio Ritossa's scientific legacy 50 years after his discovery of the heat shock response: a new view of biology, a new society, and a new journal. *Cell Stress Chaperones* 17**,** 139-143.

Defenouillere, Q., Yao, Y., Mouaikel, J., Namane, A., Galopier, A., Decourty, L., Doyen, A., Malabat, C., Saveanu, C., Jacquier, A., and Fromont-Racine, M. (2013). Cdc48-associated complex bound to 60S particles is required for the clearance of aberrant translation products. *Proc Natl Acad Sci U S A* 110**,** 5046-5051.

Dehvari, N., Mahmud, T., Persson, J., Bengtsson, T., Graff, C., Winblad, B., Ronnback, A., and Behbahani, H. (2012). Amyloid precursor protein accumulates in aggresomes in response to proteasome inhibitor. *Neurochem Int* 60**,** 533-542.

Delano, W.L.J.C.N.P.C. (2002). Pymol: An open-source molecular graphics tool. 40**,** 82-92.

Dennissen, F.J., Kholod, N., and Van Leeuwen, F.W. (2012). The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim? *Prog Neurobiol* 96**,** 190-207.

Deriziotis, P., Andre, R., Smith, D.M., Goold, R., Kinghorn, K.J., Kristiansen, M., Nathan, J.A., Rosenzweig, R., Krutauz, D., Glickman, M.H., Collinge, J., Goldberg, A.L., and Tabrizi, S.J. (2011). Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. *EMBO J* 30**,** 3065-3077.

Deshaies, R.J. (2014). Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. *BMC Biol* 12**,** 94.

Di Renzo, F., Broccia, M.L., Giavini, E., and Menegola, E. (2010). VPA-related axial skeletal defects and apoptosis: a proposed event cascade. *Reprod Toxicol* 29**,** 106-112.

Dice, J.F. (1990). Peptide sequences that target cytosolic proteins for lysosomal proteolysis. *Trends Biochem Sci* 15**,** 305-309.

Dikshit, P., Chatterjee, M., Goswami, A., Mishra, A., and Jana, N.R. (2006). Aspirin induces apoptosis through the inhibition of proteasome function. *J Biol Chem* 281**,** 29228-29235.

Do Patrocinio, A.B., Rodrigues, V., and Guidi Magalhaes, L. (2022). P53: Stability from the Ubiquitin-Proteasome System and Specific 26S Proteasome Inhibitors. *ACS Omega* 7**,** 3836-3843.

Dogra, N., and Mukhopadhyay, T. (2012). Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: a novel antiproliferative agent with a potential therapeutic implication. *J Biol Chem* 287**,** 30625-30640.

Dragovic, Z., Broadley, S.A., Shomura, Y., Bracher, A., and Hartl, F.U. (2006). Molecular chaperones of the Hsp110 family act as nucleotide exchange factors of Hsp70s. *EMBO J* 25**,** 2519-2528.

Dragunow, M., Greenwood, J.M., Cameron, R.E., Narayan, P.J., O'carroll, S.J., Pearson, A.G., and Gibbons, H.M. (2006). Valproic acid induces caspase 3-mediated apoptosis in microglial cells. *Neuroscience* 140**,** 1149-1156.

Dubey, A.R., Kinger, S., Jagtap, Y.A., Patwa, S.M., Kumar, P., Singh, S., Kumar, A., Kumar, A., and Mishra, A. (2021). Proteasome Based Molecular Strategies Against Improper Cellular Proliferation. *Cell Physiol Biochem* 55**,** 120-143.

Dubey, A.R., Mishra, R., Sundaria, N., Jagtap, Y.A., Kumar, P., Kinger, S., Choudhary, A., Jha, H.C., Prasad, A., Gutti, R.K., and Mishra, A. (2022). Resveratrol Promotes LRSAM1 E3 Ubiquitin Ligase-Dependent Degradation of Misfolded Proteins Linked with Neurodegeneration. *Cell Physiol Biochem* 56**,** 530-545.

Duttler, S., Pechmann, S., and Frydman, J. (2013). Principles of cotranslational ubiquitination and quality control at the ribosome. *Mol Cell* 50**,** 379-393.

Eisele, F., and Wolf, D.H. (2008). Degradation of misfolded protein in the cytoplasm is mediated by the ubiquitin ligase Ubr1. *FEBS Lett* 582**,** 4143-4146.

Fandrich, M., Meinhardt, J., and Grigorieff, N. (2009). Structural polymorphism of Alzheimer Abeta and other amyloid fibrils. *Prion* 3**,** 89-93.

Feng, Y., He, D., Yao, Z., and Klionsky, D.J. (2014). The machinery of macroautophagy. *Cell Res* 24**,** 24-41.

Flagmeier, P., Meisl, G., Vendruscolo, M., Knowles, T.P., Dobson, C.M., Buell, A.K., and Galvagnion, C. (2016). Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of alpha-synuclein aggregation. *Proc Natl Acad Sci U S A* 113**,** 10328-10333.

Fontaine, S.N., Zheng, D., Sabbagh, J.J., Martin, M.D., Chaput, D., Darling, A., Trotter, J.H., Stothert, A.R., Nordhues, B.A., Lussier, A., Baker, J., Shelton, L., Kahn, M., Blair, L.J., Stevens, S.M., Jr., and Dickey, C.A. (2016). DnaJ/Hsc70 chaperone complexes control the extracellular release of neurodegenerative-associated proteins. *EMBO J* 35**,** 1537-1549.

Forli, S., Huey, R., Pique, M.E., Sanner, M.F., Goodsell, D.S., and Olson, A.J. (2016). Computational protein-ligand docking and virtual drug screening with the AutoDock suite. *Nat Protoc* 11**,** 905-919.

Fredrickson, E.K., and Gardner, R.G. (2012). Selective destruction of abnormal proteins by ubiquitin-mediated protein quality control degradation. *Semin Cell Dev Biol* 23**,** 530-537.

Frydman, J., and Hohfeld, J. (1997). Chaperones get in touch: the Hip-Hop connection. *Trends Biochem Sci* 22**,** 87-92.

Frydman, J., Nimmesgern, E., Ohtsuka, K., and Hartl, F.U. (1994). Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. *Nature* 370**,** 111-117.

Fushimi, K., Long, C., Jayaram, N., Chen, X., Li, L., and Wu, J.Y. (2011). Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. *Protein Cell* 2**,** 141-149.

Galluzzi, L., Yamazaki, T., and Kroemer, G. (2018). Linking cellular stress responses to systemic homeostasis. *Nat Rev Mol Cell Biol* 19**,** 731-745.

Ganassi, M., Mateju, D., Bigi, I., Mediani, L., Poser, I., Lee, H.O., Seguin, S.J., Morelli, F.F., Vinet, J., Leo, G., Pansarasa, O., Cereda, C., Poletti, A., Alberti, S., and Carra, S. (2016). A Surveillance Function of the HSPB8-BAG3-HSP70 Chaperone Complex Ensures Stress Granule Integrity and Dynamism. *Mol Cell* 63**,** 796-810.

Gidalevitz, T., Ben-Zvi, A., Ho, K.H., Brignull, H.R., and Morimoto, R.I. (2006). Progressive disruption of cellular protein folding in models of polyglutamine diseases. *Science* 311**,** 1471-1474.

Gomez-Pastor, R., Burchfiel, E.T., and Thiele, D.J. (2018). Regulation of heat shock transcription factors and their roles in physiology and disease. *Nat Rev Mol Cell Biol* 19**,** 4-19.

Gottlicher, M. (2004). Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. *Ann Hematol* 83 Suppl 1**,** S91-92.

Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G., and Heinzel, T. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. *EMBO J* 20**,** 6969-6978.

Groll, M., Bajorek, M., Kohler, A., Moroder, L., Rubin, D.M., Huber, R., Glickman, M.H., and Finley, D. (2000). A gated channel into the proteasome core particle. *Nat Struct Biol* 7**,** 1062-1067.

Guo, Q., Lehmer, C., Martinez-Sanchez, A., Rudack, T., Beck, F., Hartmann, H., Perez-Berlanga, M., Frottin, F., Hipp, M.S., Hartl, F.U., Edbauer, D., Baumeister, W., and Fernandez-Busnadiego, R. (2018). In Situ Structure of Neuronal C9orf72 Poly-GA Aggregates Reveals Proteasome Recruitment. *Cell* 172**,** 696-705 e612.

Guzman, M.L., Swiderski, C.F., Howard, D.S., Grimes, B.A., Rossi, R.M., Szilvassy, S.J., and Jordan, C.T. (2002). Preferential induction of apoptosis for primary human leukemic stem cells. *Proc Natl Acad Sci U S A* 99**,** 16220-16225.

Han, B.R., You, B.R., and Park, W.H. (2013). Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. *Oncol Rep* 30**,** 2999-3005.

Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell* 144**,** 646-674.

Hanna, J., Guerra-Moreno, A., Ang, J., and Micoogullari, Y. (2019). Protein Degradation and the Pathologic Basis of Disease. *Am J Pathol* 189**,** 94-103.

Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E.M., Logroscino, G., Robberecht, W., Shaw, P.J., Simmons, Z., and Van Den Berg, L.H. (2017). Amyotrophic lateral sclerosis. *Nat Rev Dis Primers* 3**,** 17071.

Hartl, F.U., Bracher, A., and Hayer-Hartl, M. (2011). Molecular chaperones in protein folding and proteostasis. *Nature* 475**,** 324-332.

Hideshima, T., Bradner, J.E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S.L., and Anderson, K.C. (2005). Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. *Proc Natl Acad Sci U S A* 102**,** 8567-8572.

Hipp, M.S., Kasturi, P., and Hartl, F.U. (2019). The proteostasis network and its decline in ageing. *Nat Rev Mol Cell Biol* 20**,** 421-435.

Hohn, A., Tramutola, A., and Cascella, R. (2020). Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. *Oxid Med Cell Longev* 2020**,** 5497046.

Holmberg, C.I., Staniszewski, K.E., Mensah, K.N., Matouschek, A., and Morimoto, R.I. (2004). Inefficient degradation of truncated polyglutamine proteins by the proteasome. *EMBO J* 23**,** 4307-4318.

Holohan, C., Van Schaeybroeck, S., Longley, D.B., and Johnston, P.G. (2013). Cancer drug resistance: an evolving paradigm. *Nat Rev Cancer* 13**,** 714-726.

Hu, L.D., Wang, J., Chen, X.J., and Yan, Y.B. (2020). Lanosterol modulates proteostasis via dissolving cytosolic sequestosomes/aggresome-like induced structures. *Biochim Biophys Acta Mol Cell Res* 1867**,** 118617.

Huang, L., Ho, P., and Chen, C.H. (2007). Activation and inhibition of the proteasome by betulinic acid and its derivatives. *FEBS Lett* 581**,** 4955-4959.

Huang, Q., and Figueiredo-Pereira, M.E. (2010). Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. *Apoptosis* 15**,** 1292-1311.

Huff, M.W., and Telford, D.E. (2005). Lord of the rings--the mechanism for oxidosqualene:lanosterol cyclase becomes crystal clear. *Trends Pharmacol Sci* 26**,** 335-340.

Jacobson, T., Priya, S., Sharma, S.K., Andersson, S., Jakobsson, S., Tanghe, R., Ashouri, A., Rauch, S., Goloubinoff, P., Christen, P., and Tamas, M.J. (2017). Cadmium Causes Misfolding and Aggregation of Cytosolic Proteins in Yeast. *Mol Cell Biol* 37.

Jakobisiak, M., Lasek, W., and Golab, J. (2003). Natural mechanisms protecting against cancer. *Immunol Lett* 90**,** 103-122.

Jana, N.R., Dikshit, P., Goswami, A., Kotliarova, S., Murata, S., Tanaka, K., and Nukina, N. (2005). Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. *J Biol Chem* 280**,** 11635-11640.

Jana, N.R., Zemskov, E.A., Wang, G., and Nukina, N. (2001). Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. *Hum Mol Genet* 10**,** 1049-1059.

Jayaraj, G.G., Hipp, M.S., and Hartl, F.U. (2020). Functional Modules of the Proteostasis Network. *Cold Spring Harb Perspect Biol* 12.

Joazeiro, C.a.P. (2017). Ribosomal Stalling During Translation: Providing Substrates for Ribosome-Associated Protein Quality Control. *Annu Rev Cell Dev Biol* 33**,** 343-368.

Johannessen, C.U. (2000). Mechanisms of action of valproate: a commentatory. *Neurochem Int* 37**,** 103-110.

Johansen, T., and Lamark, T. (2011). Selective autophagy mediated by autophagic adapter proteins. *Autophagy* 7**,** 279-296.

Johnson, B.S., Snead, D., Lee, J.J., Mccaffery, J.M., Shorter, J., and Gitler, A.D. (2009). TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. *J Biol Chem* 284**,** 20329-20339.

Johnston, J.A., Illing, M.E., and Kopito, R.R. (2002). Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. *Cell Motil Cytoskeleton* 53**,** 26-38.

Johnston, J.A., Ward, C.L., and Kopito, R.R. (1998). Aggresomes: a cellular response to misfolded proteins. *J Cell Biol* 143**,** 1883-1898.

Joshi, V., Mishra, R., Upadhyay, A., Amanullah, A., Poluri, K.M., Singh, S., Kumar, A., and Mishra, A. (2019). Polyphenolic flavonoid (Myricetin) upregulated proteasomal degradation mechanisms: Eliminates neurodegenerative proteins aggregation. *J Cell Physiol* 234**,** 20900-20914.

Kaganovich, D., Kopito, R., and Frydman, J. (2008). Misfolded proteins partition between two distinct quality control compartments. *Nature* 454**,** 1088-1095.

Kampinga, H.H., Hageman, J., Vos, M.J., Kubota, H., Tanguay, R.M., Bruford, E.A., Cheetham, M.E., Chen, B., and Hightower, L.E. (2009). Guidelines for the nomenclature of the human heat shock proteins. *Cell Stress Chaperones* 14**,** 105-111.

Kampmeyer, C., Nielsen, S.V., Clausen, L., Stein, A., Gerdes, A.M., Lindorff-Larsen, K., and Hartmann-Petersen, R. (2017). Blocking protein quality control to counter hereditary cancers. *Genes Chromosomes Cancer* 56**,** 823-831.

Kang, H., Yang, Z., and Zhou, R. (2018). Lanosterol Disrupts Aggregation of Human gammaD-Crystallin by Binding to the Hydrophobic Dimerization Interface. *J Am Chem Soc* 140**,** 8479-8486.

Kannan, K., and Jain, S.K. (2000). Oxidative stress and apoptosis. *Pathophysiology* 7**,** 153-163.

Kaushik, S., and Cuervo, A.M. (2012). Chaperone-mediated autophagy: a unique way to enter the lysosome world. *Trends Cell Biol* 22**,** 407-417.

Kawagoe, R., Kawagoe, H., and Sano, K. (2002). Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. *Leukemia Research* 26**,** 495-502.

Kawaguchi, Y., Kovacs, J.J., Mclaurin, A., Vance, J.M., Ito, A., and Yao, T.P. (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. *Cell* 115**,** 727-738.

Keck, S., Nitsch, R., Grune, T., and Ullrich, O. (2003). Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. *J Neurochem* 85**,** 115-122.

Kee, H.J., Bae, E.H., Park, S., Lee, K.E., Suh, S.H., Kim, S.W., and Jeong, M.H. (2013). HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity. *Kidney Blood Press Res* 37**,** 229-239.

Keller, J.N., Hanni, K.B., and Markesbery, W.R. (2000). Impaired proteasome function in Alzheimer's disease. *J Neurochem* 75**,** 436-439.

Kirstein-Miles, J., Scior, A., Deuerling, E., and Morimoto, R.I. (2013). The nascent polypeptide-associated complex is a key regulator of proteostasis. *EMBO J* 32**,** 1451-1468.

Kisselev, A.F., and Goldberg, A.L. (2001). Proteasome inhibitors: from research tools to drug candidates. *Chem Biol* 8**,** 739-758.

Kisselev, A.F., Van Der Linden, W.A., and Overkleeft, H.S. (2012). Proteasome inhibitors: an expanding army attacking a unique target. *Chem Biol* 19**,** 99-115.

Kleiger, G., and Mayor, T. (2014). Perilous journey: a tour of the ubiquitin-proteasome system. *Trends Cell Biol* 24**,** 352-359.

Klionsky, D.J. (2005). Autophagy. *Curr Biol* 15**,** R282-283.

Komander, D., and Rape, M. (2012). The ubiquitin code. *Annu Rev Biochem* 81**,** 203-229.

Kostova, K.K., Hickey, K.L., Osuna, B.A., Hussmann, J.A., Frost, A., Weinberg, D.E., and Weissman, J.S. (2017). CAT-tailing as a fail-safe mechanism for efficient degradation of stalled nascent polypeptides. *Science* 357**,** 414-417.

Kramer, O.H., Zhu, P., Ostendorff, H.P., Golebiewski, M., Tiefenbach, J., Peters, M.A., Brill, B., Groner, B., Bach, I., Heinzel, T., and Gottlicher, M. (2003). The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. *EMBO J* 22**,** 3411-3420.

Krasnoslobodtsev, A.V., Volkov, I.L., Asiago, J.M., Hindupur, J., Rochet, J.C., and Lyubchenko, Y.L. (2013). alpha-Synuclein misfolding assessed with single molecule AFM force spectroscopy: effect of pathogenic mutations. *Biochemistry* 52**,** 7377-7386.

Kristiansen, M., Deriziotis, P., Dimcheff, D.E., Jackson, G.S., Ovaa, H., Naumann, H., Clarke, A.R., Van Leeuwen, F.W., Menendez-Benito, V., Dantuma, N.P., Portis, J.L., Collinge, J., and

Tabrizi, S.J. (2007). Disease-associated prion protein oligomers inhibit the 26S proteasome. *Mol Cell* 26**,** 175-188.

Kumar Deshmukh, F., Yaffe, D., Olshina, M.A., Ben-Nissan, G., and Sharon, M. (2019). The Contribution of the 20S Proteasome to Proteostasis. *Biomolecules* 9.

Kumar, P., Jagtap, Y.A., Patwa, S.M., Kinger, S., Dubey, A.R., Prajapati, V.K., Dhiman, R., Poluri, K.M., and Mishra, A. (2022). Autophagy based cellular physiological strategies target oncogenic progression. *J Cell Physiol* 237**,** 258-277.

Labbadia, J., and Morimoto, R.I. (2013). Huntington's disease: underlying molecular mechanisms and emerging concepts. *Trends Biochem Sci* 38**,** 378-385.

Labbadia, J., and Morimoto, R.I. (2015). The biology of proteostasis in aging and disease. *Annu Rev Biochem* 84**,** 435-464.

Laskowski, R.A., and Swindells, M.B. (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. *J Chem Inf Model* 51**,** 2778-2786.

Lee, J., Xu, Y., Zhang, T., Cui, L., Saidi, L., and Ye, Y. (2018). Secretion of misfolded cytosolic proteins from mammalian cells is independent of chaperone-mediated autophagy. *J Biol Chem* 293**,** 14359-14370.

Lee, J.G., Takahama, S., Zhang, G., Tomarev, S.I., and Ye, Y. (2016). Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. *Nat Cell Biol* 18**,** 765-776.

Lee, J.M., Ramos, E.M., Lee, J.H., Gillis, T., Mysore, J.S., Hayden, M.R., Warby, S.C., Morrison, P., Nance, M., Ross, C.A., Margolis, R.L., Squitieri, F., Orobello, S., Di Donato, S., Gomez-Tortosa, E., Ayuso, C., Suchowersky, O., Trent, R.J., Mccusker, E., Novelletto, A., Frontali, M., Jones, R., Ashizawa, T., Frank, S., Saint-Hilaire, M.H., Hersch, S.M., Rosas, H.D., Lucente, D., Harrison, M.B., Zanko, A., Abramson, R.K., Marder, K., Sequeiros, J., Paulsen, J.S., Group, P.-H.S.O.T.H.S., Landwehrmeyer, G.B., Network, R.S.O.T.E.H.S.D., Myers, R.H., Group, H.-M.S., Macdonald, M.E., Gusella, J.F., and Hsg, C.S.O.T. (2012). CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. *Neurology* 78**,** 690-695.

Leestemaker, Y., De Jong, A., Witting, K.F., Penning, R., Schuurman, K., Rodenko, B., Zaal, E.A., Van De Kooij, B., Laufer, S., Heck, A.J.R., Borst, J., Scheper, W., Berkers, C.R., and Ovaa, H. (2017). Proteasome Activation by Small Molecules. *Cell Chem Biol* 24**,** 725-736 e727.

Li, J., Uversky, V.N., and Fink, A.L. (2001). Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. *Biochemistry* 40**,** 11604-11613.

Lilienbaum, A. (2013). Relationship between the proteasomal system and autophagy. *Int J Biochem Mol Biol* 4**,** 1-26.

Lim, L., Jackson-Lewis, V., Wong, L.C., Shui, G.H., Goh, A.X., Kesavapany, S., Jenner, A.M., Fivaz, M., Przedborski, S., and Wenk, M.R. (2012). Lanosterol induces mitochondrial uncoupling and protects dopaminergic neurons from cell death in a model for Parkinson's disease. *Cell Death Differ* 19**,** 416-427.

Lin, C.Y., Loven, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee, T.I., and Young, R.A. (2012). Transcriptional amplification in tumor cells with elevated c-Myc. *Cell* 151**,** 56-67.

Liu, C.W., Corboy, M.J., Demartino, G.N., and Thomas, P.J. (2003). Endoproteolytic activity of the proteasome. *Science* 299**,** 408-411.

Lopes, U.G., Erhardt, P., Yao, R., and Cooper, G.M. (1997). p53-dependent induction of apoptosis by proteasome inhibitors. *J Biol Chem* 272**,** 12893-12896.

Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The hallmarks of aging. *Cell* 153**,** 1194-1217.

Lu, S., Hu, J., Arogundade, O.A., Goginashvili, A., Vazquez-Sanchez, S., Diedrich, J.K., Gu, J., Blum, J., Oung, S., Ye, Q., Yu, H., Ravits, J., Liu, C., Yates, J.R., 3rd, and Cleveland, D.W. (2022). Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition. *Nat Cell Biol* 24**,** 1378-1393.

Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'brien, P., Trojanowski, J.Q., and Lee, V.M. (2012). Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* 338**,** 949-953.

Lukacs, G.L., and Verkman, A.S. (2012). CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. *Trends Mol Med* 18**,** 81-91.

Ma, X.J., Wang, Y.S., Gu, W.P., and Zhao, X. (2017). The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells. *Croat Med J* 58**,** 349-357.

Maharjan, S., Oku, M., Tsuda, M., Hoseki, J., and Sakai, Y. (2014). Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition. *Sci Rep* 4**,** 5896.

Malkus, K.A., and Ischiropoulos, H. (2012). Regional deficiencies in chaperone-mediated autophagy underlie alpha-synuclein aggregation and neurodegeneration. *Neurobiol Dis* 46**,** 732-744.

Martin-Benito, J., Boskovic, J., Gomez-Puertas, P., Carrascosa, J.L., Simons, C.T., Lewis, S.A., Bartolini, F., Cowan, N.J., and Valpuesta, J.M. (2002). Structure of eukaryotic prefoldin and of its complexes with unfolded actin and the cytosolic chaperonin CCT. *EMBO J* 21**,** 6377-6386.

Masdehors, P., Merle-Beral, H., Maloum, K., Omura, S., Magdelenat, H., and Delic, J. (2000). Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. *Blood* 96**,** 269-274.

Masters, C.L., Bateman, R., Blennow, K., Rowe, C.C., Sperling, R.A., and Cummings, J.L. (2015). Alzheimer's disease. *Nat Rev Dis Primers* 1**,** 15056.

Mckinnon, C., De Snoo, M.L., Gondard, E., Neudorfer, C., Chau, H., Ngana, S.G., O'hara, D.M., Brotchie, J.M., Koprich, J.B., Lozano, A.M., Kalia, L.V., and Kalia, S.K. (2020). Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by alpha-synuclein. *Acta Neuropathol Commun* 8**,** 17.

Mcnaught, K.S., and Jenner, P. (2001). Proteasomal function is impaired in substantia nigra in Parkinson's disease. *Neurosci Lett* 297**,** 191-194.

Meacham, G.C., Patterson, C., Zhang, W., Younger, J.M., and Cyr, D.M. (2001). The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. *Nat Cell Biol* 3**,** 100-105.

Mejlvang, J., Olsvik, H., Svenning, S., Bruun, J.-A., Abudu, Y.P., Larsen, K.B., Brech, A., Hansen, T.E., Brenne, H., and Hansen, T. (2018). Starvation induces rapid degradation of selective autophagy receptors by endosomal microautophagy. *J Cell Biol* 217**,** 3640-3655.

Mishra, R., Upadhyay, A., Prajapati, V.K., and Mishra, A. (2018). Proteasome-mediated proteostasis: Novel medicinal and pharmacological strategies for diseases. *Med Res Rev* 38**,** 1916-1973.

Mori, K., Weng, S.M., Arzberger, T., May, S., Rentzsch, K., Kremmer, E., Schmid, B., Kretzschmar, H.A., Cruts, M., Van Broeckhoven, C., Haass, C., and Edbauer, D. (2013). The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. *Science* 339**,** 1335-1338.

Morimoto, R.I., Driessen, A.J., Hegde, R.S., and Langer, T. (2011). The life of proteins: the good, the mostly good and the ugly. *Nat Struct Mol Biol* 18**,** 1-4.

Morreale, F.E., and Walden, H. (2016). Types of Ubiquitin Ligases. *Cell* 165**,** 248-248 e241.

Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., and Olson, A.J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J Comput Chem* 30**,** 2785-2791.

Nakamura, T., and Lipton, S.A. (2009). Cell death: protein misfolding and neurodegenerative diseases. *Apoptosis* 14**,** 455-468.

Nakatogawa, H., Suzuki, K., Kamada, Y., and Ohsumi, Y. (2009). Dynamics and diversity in autophagy mechanisms: lessons from yeast. *Nat Rev Mol Cell Biol* 10**,** 458-467.

Nedelsky, N.B., Todd, P.K., and Taylor, J.P. (2008). Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. *Biochim Biophys Acta* 1782**,** 691-699.

Nillegoda, N.B., Kirstein, J., Szlachcic, A., Berynskyy, M., Stank, A., Stengel, F., Arnsburg, K., Gao, X., Scior, A., Aebersold, R., Guilbride, D.L., Wade, R.C., Morimoto, R.I., Mayer, M.P., and Bukau, B. (2015). Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. *Nature* 524**,** 247-251.

Njomen, E., Osmulski, P.A., Jones, C.L., Gaczynska, M., and Tepe, J.J. (2018). Small Molecule Modulation of Proteasome Assembly. *Biochemistry* 57**,** 4214-4224.

Njomen, E., and Tepe, J.J. (2019). Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders. *J Med Chem* 62**,** 6469-6481.

Nunes, A.T., and Annunziata, C.M. (2017). Proteasome inhibitors: structure and function. *Semin Oncol* 44**,** 377-380.

Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, W.J., Jr., Lee, K.P., and Boise, L.H. (2006). Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. *Blood* 107**,** 4907-4916.

Oddo, S. (2008). The ubiquitin-proteasome system in Alzheimer's disease. *J Cell Mol Med* 12**,** 363-373.

Olzmann, J.A., Li, L., and Chin, L.S. (2008). Aggresome formation and neurodegenerative diseases: therapeutic implications. *Curr Med Chem* 15**,** 47-60.

Olzscha, H., Schermann, S.M., Woerner, A.C., Pinkert, S., Hecht, M.H., Tartaglia, G.G., Vendruscolo, M., Hayer-Hartl, M., Hartl, F.U., and Vabulas, R.M. (2011). Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. *Cell* 144**,** 67-78.

Palombella, V.J., Rando, O.J., Goldberg, A.L., and Maniatis, T. (1994). The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. *Cell* 78**,** 773-785.

Palsamy, P., Bidasee, K.R., and Shinohara, T. (2014). Valproic acid suppresses Nrf2/Keap1 dependent antioxidant protection through induction of endoplasmic reticulum stress and Keap1 promoter DNA demethylation in human lens epithelial cells. *Exp Eye Res* 121**,** 26-34.

Panieri, E., and Santoro, M.M. (2016). ROS homeostasis and metabolism: a dangerous liason in cancer cells. *Cell Death Dis* 7**,** e2253.

Paradis, F.H., and Hales, B.F. (2015). Valproic Acid Induces the Hyperacetylation of P53, Expression of P53 Target Genes, and Markers of the Intrinsic Apoptotic Pathway in Midorganogenesis Murine Limbs. *Birth Defects Res B Dev Reprod Toxicol* 104**,** 177-183.

Park, J.E., Miller, Z., Jun, Y., Lee, W., and Kim, K.B. (2018). Next-generation proteasome inhibitors for cancer therapy. *Transl Res* 198**,** 1-16.

Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* 25**,** 1605-1612.

Phillips, A., Bullock, T., and Plant, N. (2003). Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO. *Toxicology* 192**,** 219-227.

Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkmann, J., Schrag, A.E., and Lang, A.E. (2017). Parkinson disease. *Nat Rev Dis Primers* 3**,** 17013.

Pohl, C., and Dikic, I. (2019). Cellular quality control by the ubiquitin-proteasome system and autophagy. *Science* 366**,** 818-822.

Polier, S., Dragovic, Z., Hartl, F.U., and Bracher, A. (2008). Structural basis for the cooperation of Hsp70 and Hsp110 chaperones in protein folding. *Cell* 133**,** 1068-1079.

Pratt, J.M., Petty, J., Riba-Garcia, I., Robertson, D.H., Gaskell, S.J., Oliver, S.G., and Beynon, R.J. (2002). Dynamics of protein turnover, a missing dimension in proteomics. *Mol Cell Proteomics* 1**,** 579-591.

Preissler, S., and Deuerling, E. (2012). Ribosome-associated chaperones as key players in proteostasis. *Trends Biochem Sci* 37**,** 274-283.

Qiu, X.B., Shao, Y.M., Miao, S., and Wang, L. (2006). The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. *Cell Mol Life Sci* 63**,** 2560-2570.

Rao, R.V., and Bredesen, D.E. (2004). Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. *Curr Opin Cell Biol* 16**,** 653-662.

Riemenschneider, H., Guo, Q., Bader, J., Frottin, F., Farny, D., Kleinberger, G., Haass, C., Mann, M., Hartl, F.U., Baumeister, W., Hipp, M.S., Meissner, F., Fernandez-Busnadiego, R., and Edbauer, D. (2022). Gel-like inclusions of C-terminal fragments of TDP-43 sequester stalled proteasomes in neurons. *EMBO Rep* 23**,** e53890.

Ritossa, F. (1962). A new puffing pattern induced by temperature shock and DNP in drosophila. *Experientia* 18**,** 571-573.

Ritossa, F.M. (1964). Experimental Activation of Specific Loci in Polytene Chromosomes of Drosophila. *Exp Cell Res* 35**,** 601-607.

Rodina, A., Wang, T., Yan, P., Gomes, E.D., Dunphy, M.P., Pillarsetty, N., Koren, J., Gerecitano, J.F., Taldone, T., Zong, H., Caldas-Lopes, E., Alpaugh, M., Corben, A., Riolo, M., Beattie, B., Pressl, C., Peter, R.I., Xu, C., Trondl, R., Patel, H.J., Shimizu, F., Bolaender, A., Yang, C., Panchal, P., Farooq, M.F., Kishinevsky, S., Modi, S., Lin, O., Chu, F., Patil, S., Erdjument-Bromage, H., Zanzonico, P., Hudis, C., Studer, L., Roboz, G.J., Cesarman, E., Cerchietti, L., Levine, R., Melnick, A., Larson, S.M., Lewis, J.S., Guzman, M.L., and Chiosis, G. (2016). The epichaperome is an integrated chaperome network that facilitates tumour survival. *Nature* 538**,** 397-401.

Rosenblatt, A., Kumar, B.V., Mo, A., Welsh, C.S., Margolis, R.L., and Ross, C.A. (2012). Age, CAG repeat length, and clinical progression in Huntington's disease. *Mov Disord* 27**,** 272-276.

Rosenzweig, R., Nillegoda, N.B., Mayer, M.P., and Bukau, B. (2019). The Hsp70 chaperone network. *Nat Rev Mol Cell Biol* 20**,** 665-680.

Ross, C.A., and Poirier, M.A. (2004). Protein aggregation and neurodegenerative disease. *Nat Med* 10 Suppl**,** S10-17.

Roth, D.M., and Balch, W.E. (2011). Modeling general proteostasis: proteome balance in health and disease. *Curr Opin Cell Biol* 23**,** 126-134.

Rusmini, P., Cristofani, R., Tedesco, B., Ferrari, V., Messi, E., Piccolella, M., Casarotto, E., Chierichetti, M., Cicardi, M.E., Galbiati, M., Geroni, C., Lombardi, P., Crippa, V., and Poletti, A. (2020). Enhanced Clearance of Neurotoxic Misfolded Proteins by the Natural Compound Berberine and Its Derivatives. *Int J Mol Sci* 21.

Russell, R.C., Tian, Y., Yuan, H., Park, H.W., Chang, Y.Y., Kim, J., Kim, H., Neufeld, T.P., Dillin, A., and Guan, K.L. (2013). ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. *Nat Cell Biol* 15**,** 741-750.

Sahu, I., and Glickman, M.H. (2021). Proteasome in action: substrate degradation by the 26S proteasome. *Biochem Soc Trans* 49**,** 629-644.

Sannino, S., and Brodsky, J.L. (2017). Targeting protein quality control pathways in breast cancer. *BMC Biol* 15**,** 109.

Scherpereel, A., Berghmans, T., Lafitte, J.J., Colinet, B., Richez, M., Bonduelle, Y., Meert, A.P., Dhalluin, X., Leclercq, N., Paesmans, M., Willems, L., Sculier, J.P., and European Lung Cancer Working, P. (2011). Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. *Eur Respir J* 37**,** 129-135.

Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F.U., and Moarefi, I. (2000). Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. *Cell* 101**,** 199-210.

Schmidt, M., and Finley, D. (2014). Regulation of proteasome activity in health and disease. *Biochim Biophys Acta* 1843**,** 13-25.

Schrader, J., Henneberg, F., Mata, R.A., Tittmann, K., Schneider, T.R., Stark, H., Bourenkov, G., and Chari, A. (2016). The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. *Science* 353**,** 594-598.

Schwertheim, S., Worm, K., Schmid, K.W., and Sheu-Grabellus, S.Y. (2014). Valproic acid downregulates NF-kappaB p50 activity and IRAK-1 in a progressive thyroid carcinoma cell line. *Horm Metab Res* 46**,** 181-186.

Shao, S., Brown, A., Santhanam, B., and Hegde, R.S. (2015). Structure and assembly pathway of the ribosome quality control complex. *Mol Cell* 57**,** 433-444.

Shen, P.S., Park, J., Qin, Y., Li, X., Parsawar, K., Larson, M.H., Cox, J., Cheng, Y., Lambowitz, A.M., Weissman, J.S., Brandman, O., and Frost, A. (2015). Protein synthesis. Rqc2p and 60S ribosomal subunits mediate mRNA-independent elongation of nascent chains. *Science* 347, 75-78.

Sherman, M.Y., and Goldberg, A.L. (2001). Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. *Neuron* 29, 15-32.

Shiber, A., and Ravid, T. (2014). Chaperoning proteins for destruction: diverse roles of Hsp70 chaperones and their co-chaperones in targeting misfolded proteins to the proteasome. *Biomolecules* 4, 704-724.

Singh, D., Gupta, S., Verma, I., Morsy, M.A., Nair, A.B., and Ahmed, A.F. (2021). Hidden pharmacological activities of valproic acid: A new insight. *Biomed Pharmacother* 142, 112021.

Sivandzade, F., Bhalerao, A., and Cucullo, L. (2019). Analysis of the Mitochondrial Membrane Potential Using the Cationic JC-1 Dye as a Sensitive Fluorescent Probe. *Bio Protoc* 9.

Smiley, S.T., Reers, M., Mottola-Hartshorn, C., Lin, M., Chen, A., Smith, T.W., Steele, G.D., Jr., and Chen, L.B. (1991). Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. *Proc Natl Acad Sci U S A* 88, 3671-3675.

Song, B.L., Javitt, N.B., and Debose-Boyd, R.A. (2005). Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. *Cell Metab* 1, 179-189.

Soto, C. (2003). Unfolding the role of protein misfolding in neurodegenerative diseases. *Nat Rev Neurosci* 4, 49-60.

Soto, C., and Pritzkow, S. (2018). Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. *Nat Neurosci* 21, 1332-1340.

Spitz, F., and Furlong, E.E. (2012). Transcription factors: from enhancer binding to developmental control. *Nat Rev Genet* 13, 613-626.

Stankiewicz, M., Nikolay, R., Rybin, V., and Mayer, M.P. (2010). CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates. *FEBS J* 277, 3353-3367.

Stathopulos, P.B., Rumfeldt, J.A., Karbassi, F., Siddall, C.A., Lepock, J.R., and Meiering, E.M. (2006). Calorimetric analysis of thermodynamic stability and aggregation for apo and holo amyotrophic lateral sclerosis-associated Gly-93 mutants of superoxide dismutase. *J Biol Chem* 281, 6184-6193.

Sullivan, P.G., Dragicevic, N.B., Deng, J.H., Bai, Y., Dimayuga, E., Ding, Q., Chen, Q., Bruce-Keller, A.J., and Keller, J.N. (2004). Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. *J Biol Chem* 279, 20699-20707.

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 71, 209-249.

Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., Mccampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., and Hodgson, R. (2017). Protein misfolding in neurodegenerative diseases: implications and strategies. *Transl Neurodegener* 6, 6.

Takai, N., Desmond, J.C., Kumagai, T., Gui, D., Said, J.W., Whittaker, S., Miyakawa, I., and Koeffler, H.P. (2004a). Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. *Clin Cancer Res* 10, 1141-1149.

Takai, N., Kawamata, N., Gui, D., Said, J.W., Miyakawa, I., and Koeffler, H.P. (2004b). Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. *Cancer* 101, 2760-2770.

Tamas, M.J., Sharma, S.K., Ibstedt, S., Jacobson, T., and Christen, P. (2014). Heavy metals and metalloids as a cause for protein misfolding and aggregation. *Biomolecules* 4, 252-267.

Tanaka, K. (2009). The proteasome: overview of structure and functions. *Proc Jpn Acad Ser B Phys Biol Sci* 85, 12-36.

Thelen, P., Schweyer, S., Hemmerlein, B., Wuttke, W., Seseke, F., and Ringert, R.H. (2004). Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. *Int J Oncol* 24**,** 25-31.

Thibaudeau, T.A., Anderson, R.T., and Smith, D.M. (2018). A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers. *Nat Commun* 9**,** 1097.

Thrun, A., Garzia, A., Kigoshi-Tansho, Y., Patil, P.R., Umbaugh, C.S., Dallinger, T., Liu, J., Kreger, S., Patrizi, A., Cox, G.A., Tuschl, T., and Joazeiro, C.a.P. (2021). Convergence of mammalian RQC and C-end rule proteolytic pathways via alanine tailing. *Mol Cell* 81**,** 2112-2122 e2117.

Tran, L.N.K., Kichenadasse, G., Butler, L.M., Centenera, M.M., Morel, K.L., Ormsby, R.J., Michael, M.Z., Lower, K.M., and Sykes, P.J. (2017). The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer. *Mol Cancer Ther* 16**,** 2689-2700.

Trott, O., and Olson, A.J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* 31**,** 455-461.

Tseng, B.P., Green, K.N., Chan, J.L., Blurton-Jones, M., and Laferla, F.M. (2008). Abeta inhibits the proteasome and enhances amyloid and tau accumulation. *Neurobiol Aging* 29**,** 1607-1618.

Tung, E.W., and Winn, L.M. (2011). Valproic acid-induced DNA damage increases embryonic p27(KIP1) and caspase-3 expression: a mechanism for valproic-acid induced neural tube defects. *Reprod Toxicol* 32**,** 255-260.

Upadhyay, A., Amanullah, A., Mishra, R., Kumar, A., and Mishra, A. (2018). Lanosterol Suppresses the Aggregation and Cytotoxicity of Misfolded Proteins Linked with Neurodegenerative Diseases. *Mol Neurobiol* 55**,** 1169-1182.

Valastyan, J.S., and Lindquist, S. (2014). Mechanisms of protein-folding diseases at a glance. *Dis Model Mech* 7**,** 9-14.

Verhoef, L.G., Lindsten, K., Masucci, M.G., and Dantuma, N.P. (2002). Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. *Hum Mol Genet* 11**,** 2689-2700.

Vihervaara, A., and Sistonen, L. (2014). HSF1 at a glance. *J Cell Sci* 127**,** 261-266.

Vinh, D.B., and Drubin, D.G. (1994). A yeast TCP-1-like protein is required for actin function in vivo. *Proc Natl Acad Sci U S A* 91**,** 9116-9120.

Vogiatzi, T., Xilouri, M., Vekrellis, K., and Stefanis, L. (2008). Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. *J Biol Chem* 283**,** 23542-23556.

Vos, M.J., Hageman, J., Carra, S., and Kampinga, H.H. (2008). Structural and functional diversities between members of the human HSPB, HSPH, HSPA, and DNAJ chaperone families. *Biochemistry* 47**,** 7001-7011.

Waelter, S., Boeddrich, A., Lurz, R., Scherzinger, E., Lueder, G., Lehrach, H., and Wanker, E.E. (2001). Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. *Mol Biol Cell* 12**,** 1393-1407.

Wallace, A.C., Laskowski, R.A., and Thornton, J.M. (1995). LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein Eng* 8**,** 127-134.

Wang, D., Fang, C., Zong, N.C., Liem, D.A., Cadeiras, M., Scruggs, S.B., Yu, H., Kim, A.K., Yang, P., Deng, M., Lu, H., and Ping, P. (2013a). Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human. *Mol Cell Proteomics* 12**,** 3793-3802.

Wang, F., Durfee, L.A., and Huibregtse, J.M. (2013b). A cotranslational ubiquitination pathway for quality control of misfolded proteins. *Mol Cell* 50**,** 368-378.

Wang, Z.V., and Hill, J.A. (2015). Protein quality control and metabolism: bidirectional control in the heart. *Cell Metab* 21**,** 215-226.

Ward, C.L., and Kopito, R.R. (1994). Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. *J Biol Chem* 269**,** 25710-25718.

Ward, C.L., Omura, S., and Kopito, R.R. (1995). Degradation of CFTR by the ubiquitin-proteasome pathway. *Cell* 83**,** 121-127.

Wiedmann, B., Sakai, H., Davis, T.A., and Wiedmann, M. (1994). A protein complex required for signal-sequence-specific sorting and translocation. *Nature* 370**,** 434-440.

Willmund, F., Del Alamo, M., Pechmann, S., Chen, T., Albanese, V., Dammer, E.B., Peng, J., and Frydman, J. (2013). The cotranslational function of ribosome-associated Hsp70 in eukaryotic protein homeostasis. *Cell* 152**,** 196-209.

Wilson, D.M., 3rd, Cookson, M.R., Van Den Bosch, L., Zetterberg, H., Holtzman, D.M., and Dewachter, I. (2023). Hallmarks of neurodegenerative diseases. *Cell* 186**,** 693-714.

Wong, E., and Cuervo, A.M. (2010). Autophagy gone awry in neurodegenerative diseases. *Nat Neurosci* 13**,** 805-811.

Ximenes, J.C., De Oliveira Goncalves, D., Siqueira, R.M., Neves, K.R., Santos Cerqueira, G., Correia, A.O., Felix, F.H., Leal, L.K., De Castro Brito, G.A., Da Graca Naffah-Mazzacorati, M., and Viana, G.S. (2013). Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. *Naunyn Schmiedebergs Arch Pharmacol* 386**,** 575-587.

Xu, Y., Cui, L., Dibello, A., Wang, L., Lee, J., Saidi, L., Lee, J.G., and Ye, Y. (2018). DNAJC5 facilitates USP19-dependent unconventional secretion of misfolded cytosolic proteins. *Cell Discov* 4**,** 11.

Zaffagnini, G., and Martens, S. (2016). Mechanisms of Selective Autophagy. *J Mol Biol* 428**,** 1714-1724.

Zhao, L., Chen, X.J., Zhu, J., Xi, Y.B., Yang, X., Hu, L.D., Ouyang, H., Patel, S.H., Jin, X., Lin, D., Wu, F., Flagg, K., Cai, H., Li, G., Cao, G., Lin, Y., Chen, D., Wen, C., Chung, C., Wang, Y., Qiu, A., Yeh, E., Wang, W., Hu, X., Grob, S., Abagyan, R., Su, Z., Tjondro, H.C., Zhao, X.J., Luo, H., Hou, R., Jefferson, J., Perry, P., Gao, W., Kozak, I., Granet, D., Li, Y., Sun, X., Wang, J., Zhang, L., Liu, Y., Yan, Y.B., and Zhang, K. (2015). Lanosterol reverses protein aggregation in cataracts. *Nature* 523**,** 607-611.

Zheng, C., Geetha, T., and Babu, J.R. (2014). Failure of ubiquitin proteasome system: risk for neurodegenerative diseases. *Neurodegener Dis* 14**,** 161-175.

Zhou, H., Yang, Z., Tian, X., Chen, L., Lee, S., Huynh, T., Ge, C., and Zhou, R. (2019). Lanosterol Disrupts the Aggregation of Amyloid-beta Peptides. *ACS Chem Neurosci* 10**,** 4051-4060.

Zuiderweg, E.R., Hightower, L.E., and Gestwicki, J.E. (2017). The remarkable multivalency of the Hsp70 chaperones. *Cell Stress Chaperones* 22**,** 173-189.

…